Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Delayed First Injection Of The Once-a-month Injectable Contraceptive Containing 25 Mg Of Medroxyprogesterone Acetate And 5 Mg Of E2-cypionate: Effects On Ovarian Function|
|Abstract:||Objective: To assess whether women who were administered the first injection of DMPA+E2C on day 7 of their menstrual cycle (delayed injection) exhibit the same degree of ovarian suppression as women who receive it on day 5 of their menstrual cycle. Design: Multicenter, randomized controlled trial.Setting: Reproductive health clinics. Patient(s): Women aged between 18 and 38 years (inclusive) willing to use DMPA+E2C as their method of contraception. Intervention(s): Participants received a DMPA+E2C injection on day 5 (control group, n = 41) or day 7 (delayed-injection group, n = 117) of their menstrual cycle. Main Outcome Measure(s): Ovarian activity and follicular development determined by serial serum progesterone levels and vaginal ultrasound. Result(s): Participants who received DMPA+E2C on day 5 of their menstrual cycle (control group) exhibited no more than limited follicular growth (no follicle >16 mm). Of those women who received DMPA+E2C on day 7 of their menstrual cycle (delayed-injection group), 21 (18%) showed some follicular growth, of whom 4 (3%) ovulated. Conclusion(s): The first injection of DMPA+E2C given on day 7 of a menstrual cycle does not provide the same inhibition of ovarian activity as that observed when it is administered on day 5 of the menstrual cycle. Copyright © 2001 American Society for Reproductive Medicine.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.